Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA <LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. 2. To evaluate the safety and tolerability of MK-5172 in combination with MK-8742.
Critère d'inclusion
- Hepatitis C